Explainer
How does a peptide get on the 503A bulks list?
Short answer · as of 2026-10-05
A substance is nominated with supporting documentation, FDA consults the Pharmacy Compounding Advisory Committee and the U.S. Pharmacopeial Convention, and FDA then proposes and finalizes a regulation through notice and comment. The committee's vote is advice, not a listing. For the seven peptides discussed in July 2026, FDA's briefing proposed that none be included, and outlets report the panel backed six.
By Peptide Industry Gossip · Published · General explanation, not legal or medical advice. Disclaimer.
Why the list matters
Under section 503A, a bulk drug substance may be used in compounding if it meets a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on a list the Secretary develops by regulation. The 503A bulks list is that list.
The three steps
- Nomination: interested parties submit a substance with supporting documentation.
- Consultation: FDA consults the Pharmacy Compounding Advisory Committee and the U.S. Pharmacopeial Convention.
- Rulemaking: FDA issues proposed and final regulations through notice and comment.
What is on it now
FDA's 503A page says a final regulation in February 2019 placed six substances on the list. We read that through a summary, so check FDA's page for the current list.
Where the July 2026 peptide panel fits
FDA's briefing document for the July 23-24, 2026 meeting proposed that BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon not be included on the list. Outlets report the panel backed six of the seven by narrow margins. A committee vote is the consultation step. It does not add a substance to the list, which still needs a regulation.
What it does not mean
- A panel vote does not change what FDA's pages say today, and the pages we retrieved on Oct. 5 did not show a category change for BPC-157.
- Listing would make a substance eligible for 503A compounding. It would not make a compounded drug FDA-approved.
Sources
- FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) · captured 2026-10-05 · tier 1
- Legal Information Institute, 21 U.S.C. 353a (FD&C Act section 503A): Pharmacy compounding · captured 2026-10-05 · tier 1
- FDA, Briefing document for the Pharmacy Compounding Advisory Committee, July 23-24, 2026 · captured 2026-10-05 · tier 1
Quotes are from the FDA documents above, retrieved Oct. 5, 2026. FDA can revise those pages. See something wrong? Request a correction.